Last edition
News about "mycosis fungoides,"
Sobi-Innate Pharma Partnership Advances Lacutamab Phase 3 Study
The partnership between Sobi and Innate Pharma will support the TELLOMAK-3 confirmatory Phase 3 trial in CTCL and development of lacutamab in Sézary syndrome.
Mycosis Fungoides | 18/09/2026 | By News Bureau
Innate Pharma Partners with Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma and Sobi have partnered to advance lacutamab in T-cell lymphoma, with Innate leading the TELLOMAK-3 phase 3 trial in CTCL.
Mycosis Fungoides | 11/08/2026 | By News Bureau
Sobi and Innate Pharma Partner to Advance Lacutamab in T-Cell Lymphoma
Sobi and Innate Pharma partners to advance lacutamab into the TELLOMAK-3 Phase 3 trial, supporting its potential accelerated approval in Sézary syndrome and future development across cutaneous T-cell lymphoma.
Mycosis Fungoides | 10/08/2026 | By News Bureau | 102
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy